Diana Dias da Silva

Diana Dias Silva (DDS) is a Lecturer and Research Associate at the University Institute of Health Sciences (IUCS-CESPU) and at the UCIBIO-REQUIMTE, Faculty of Pharmacy of the University of Porto (FFUP), Portugal, who possesses a well-established curriculum on experimentation and teaching in the field of Toxicology, Pharmacology and Forensic Sciences. She was born in 1983, and since 2007 holds a 6-year PharmD degree granted by FFUP with a final classification of 16/20 (Grade A). In 2009, after finishing the Specialization Course in Forensic Sciences of the Faculty of Medicine of the University of Porto (FMUP), Portugal, she was awarded with an FCT fellowship to carry out her doctoral studies at The Laboratory of Toxicology of FFUP and at The Centre for Toxicology of the UCL London (UK). In 2013, she obtained her PhD in Forensic Sciences (Toxicology speciality) by FMUP, with honour and distinction, and in the same year she awarded the European PhD by Rector Dispatch. During her PhD, DDS focused on the study of toxicodynamic and toxicokinetic interactions of amphetamines. Since then, DDS develops scientific and academic activity in the areas of Toxicology and Pharmacology of Psychoactive Substances, Pharmaceuticals, Environmental Carcinogens and Nanoparticles, in their preclinical, clinical and forensic aspects. She successfully completed 4 Postdoctoral projects in Clinical, Analytical and Forensic Toxicology, and has experience in the teaching of 19 Curricular Units of 5 graduation (Forensic Sciences-IUCS; Biomedical Sciences-IUCS; Pharmaceutical Sciences-FFUP; Medicine-FMUP; Nursing-ESSLei), 3 MSc (Forensic Sciences and Laboratory Techniques-IUCS; Forensic Sciences-FMUP; Clinical, Analytical and Forensic Toxicology-FFUP) and 3 PhD programmes (Biological Sciences Applied to Health-IUCS; Forensic Sciences-FMUP; Sustainable Chemistry-FCT/UNL). She is a lecturer at IUCS-CESPU (since 2016), FMUP (since 2018), FFUP (since 2020), and The School of Health Sciences of Polytechnic of Leiria (ESSLei; since 2021). DDS has experience as scientific supervisor of PhD students (4 ongoing), MSc students (17 completed; 6 ongoing), Integrated Master students (9 completed), Bachelor students (3 completed; 1 ongoing), and Mobility students (29 completed); and was a juror in 35 academic MSc and PhD examinations. DDS is vice-president of the Board of the General Meeting of the Portuguese Association of Forensic Sciences (APCF; http://apcforenses.org) and member of the Coordinating Committee of the TOXRUN – Toxicology Research Unit (https://toxrun.iucs.cespu.pt). She is member of several national and international Committees for Evaluation of Research Projects submitted for funding (including the Czech Science Foundation). She was manuscript referee for 24 indexed scientific journals (ISI) in the field of Toxicology and Pharmacology, edited the Special Issues "Insights into the Pharmacology, Toxicology and Clinical Applications of Hallucinogens" [JCM; IF 3.303] and "Psychoactive Substances in Neuronal Development" [Int J Mol Sci; IF 4.183], and since 2020 is Editorial Board Member of Current Forensic Science (Bentham Science Publishers). The work of DDS enjoys further international recognition, as evidenced by the integration of the teams of two EU-commissioned Open Access Educational Projects, namely TOX-OER (www.toxoer.com) and Erasmus+OEMONOM; and of several funded projects - DDS worked as a team member or PI in 21 funded projects (8 international) and has been in strike collaboration with several national and international research groups. DDS presented her research in 32 national and international conferences (Portugal, USA, France, Germany, Spain, Sweden, among others) with more than 55 oral communications and 72 posters. DDS co-authors 27 abstracts and 52 articles (being corresponding/first/last author of 95%, representing more than 2,231 citations according to Google Scholar; h-index of 18) published in prestigious ISI-indexed international journals, in top journals (Q1) in the field. Her current work focuses on i) scrutinizing the pharmacological potential of psilocybin/psilocyn to be used in the treatment of depression in cancer patients; ii) understanding the role of synthetic cannabinoids in the onset of neurodevelopment and neurodegenerative disorders; iii) characterizing the toxicological and toxicokinetic profile of psychoactive drugs, using in vivo and in vitro experimental models; iv) evaluating the mixture effects of drugs of abuse and environmental carcinogens, using genotoxic and metabolomic approaches; and v) characterizing the biokinetic properties and mechanistic toxicity of nanoparticles with biomedical applications.